Texas Oncology
In research, Texas Oncology stands highest in Medicine (#5,846 of 10,443 worldwide) and Health Sciences (#7,555 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Oncology — Oncology is 14.1× its share of world research.
- World rank, 2022–2025
- #12,839 of 28,054 · #8,682 all time
- Rank in United States
- #1,770 of 4,192
- Research works
- 1.2k ▲ 5% vs 2013–17
- Citations
- 38k 30.6 per fractional work
- Top-10% rate
- 11.1% record average 16.5%
- Open access
- 28% world 28%
What is Texas Oncology known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #5,846 of 10,443 | 14.2% | 143 | #2976 | |
| Health SciencesDomain | #7,555 of 11,982 | 13.7% | 149 | #4013 |
Each strip is that field’s whole ranked pool, with the notch where Texas Oncology sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Texas Oncology specialise in?
Where its research is concentrated relative to its size: Oncology takes 14.1× the share of its output that it takes of world research.
- OncologySubfield · 41.5 works14×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 2.9×. Every wedge is a field page.
- Medicine 2.9×
- Biochemistry, Genetics and Molecular Biology 2.7×
- Immunology and Microbiology 2.6×
- Economics, Econometrics and Finance 2.4×
- Computer Science 1.4×
- Pharmacology, Toxicology and Pharmaceutics 1.0×
- Decision Sciences 0.9×
- Health Professions 0.8×
- Business, Management and Accounting 0.6×
- Nursing 0.4×
- Neuroscience 0.3×
- Dentistry 0.3×
- Chemistry 0.2×
- Physics and Astronomy 0.2×
- Mathematics 0.2×
- Engineering 0.1×
- Social Sciences 0.1×
- Materials Science 0.1×
- Psychology 0.1×
- Environmental Science 0.1×
- Agricultural and Biological Sciences 0.0×
- Earth and Planetary Sciences 0.0×
Who are the top researchers at Texas Oncology?
Ranked on the composite score, Thomas E. Hutson, Joyce O’Shaughnessy and Joyce O’Shaughnessy lead among researchers whose main affiliation is Texas Oncology.
- 1 Thomas E. Hutson United States · #7,008 worldwide 964 citations · 60 works
- 2 Joyce O’Shaughnessy United States · #23,832 worldwide 579 citations · 85 works
- 3 Joyce O’Shaughnessy United States · #28,446 worldwide 357 citations · 55 works
- 4 Roger M. Lyons United States · #75,498 worldwide 209 citations · 30 works
- 5 Lina Asmar United States · #371,710 worldwide 79 citations · 34 works
- 6 Debra A. Patt United States · #382,113 worldwide 47 citations · 31 works
- 7 Donald Richards United States · #588,364 worldwide 151 citations · 62 works
- 8 Kristi A. Boehm United States · #668,505 worldwide 53 citations · 17 works
- 9 Joanne L. Blum United States · #718,521 worldwide 41 citations · 25 works
- 10 Yana Zhang United States · #930,025 worldwide 19 citations · 17 works
Which keywords describe research at Texas Oncology?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Immunotherapy, Tumor Microenvironment, Metastatic Breast Cancer, Targeted Therapy, Prognostic Factors and Big Data.
- Genomic Instability
- HER2
- Molecular Subtypes
- Trastuzumab
- Lymphoma
- PET Imaging
- Palbociclib
- Cell Cycle Control
- Resource Management
- Neoadjuvant Therapy
- Cancer Therapy
- Cost of Care
- Metastasis
- Clinical Practice Guidelines
- Distributed Systems
- Clinical Trials
- Targeted Therapy
- Metastatic Breast Cancer
- Big Data
- Breast Cancer
- Chemotherapy
- Immunotherapy
- Tumor Microenvironment
- Prognostic Factors
- Quality of Life
- Cloud Computing
- Survival Analysis
- Energy Efficiency
- Metastatic
- Financial Toxicity
- Precision Medicine
- Radiotherapy
- Rituximab
- CDK4/6 Inhibitors
- MapReduce
- Virtualization
- Molecular Characterization
- Receptor tyrosine kinases
- EGFR
- Monoclonal Antibody
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy25▲ 14×21 topics
- Breast Cancer19▲ 30×9 topics
- Immunotherapy18▲ 9.5×17 topics
- Big Data14▲ 5.7×7 topics
- Tumor Microenvironment13▲ 12×8 topics
- Metastatic Breast Cancer13▲ 86×2 topics
- Prognostic Factors12▲ 11×13 topics
- Targeted Therapy12▲ 21×5 topics
- Quality of Life12▲ 3.2×16 topics
- Clinical Trials12▲ 6.7×11 topics
- Cloud Computing10▲ 14×4 topics
- Distributed Systems10▲ 23×3 topics
- Survival Analysis10▲ 14×7 topics
- Clinical Practice Guidelines10▲ 6.8×10 topics
- Energy Efficiency9▲ 3.8×6 topics
- Metastasis9▲ 10×10 topics
- Metastatic9▲ 56×2 topics
- Cost of Care9▲ 117×1 topic
- Financial Toxicity9▲ 117×1 topic
- Cancer Therapy9▲ 5.9×14 topics
- Precision Medicine9▲ 7.1×6 topics
- Neoadjuvant Therapy8▲ 14×5 topics
- Radiotherapy8▲ 8.3×10 topics
- Resource Management8▲ 18×2 topics
- Rituximab8▲ 21×3 topics
- Cell Cycle Control8▲ 102×2 topics
- CDK4/6 Inhibitors8▲ 122×1 topic
- Palbociclib8▲ 122×1 topic
- MapReduce8▲ 51×1 topic
- PET Imaging8▲ 18×4 topics
- Virtualization8▲ 38×1 topic
- Lymphoma8▲ 18×3 topics
- Molecular Characterization7▲ 16×4 topics
- Trastuzumab7▲ 60×2 topics
- Receptor tyrosine kinases7▲ 75×2 topics
- Molecular Subtypes7▲ 31×3 topics
- EGFR7▲ 90×1 topic
- HER27▲ 90×1 topic
- Monoclonal Antibody7▲ 49×2 topics
- Genomic Instability6▲ 22×3 topics
Which research topics does Texas Oncology publish most on?
By volume in 2022–2025: Economic and Financial Impacts of Cancer, Advanced Breast Cancer Therapies, Cloud Computing and Resource Management and HER2/EGFR in Cancer Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Economic and Financial Impacts of Cancer Economics and Econometrics 9 works
- 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 8 works
- 3 Cloud Computing and Resource Management Information Systems 8 works
- 4 HER2/EGFR in Cancer Research Oncology 7 works
- 5 Cancer Immunotherapy and Biomarkers Oncology 6 works
- 6 Cancer Genomics and Diagnostics Cancer Research 6 works
- 7 Cancer Treatment and Pharmacology Oncology 5 works
- 8 Ovarian cancer diagnosis and treatment Reproductive Medicine 4 works
- 9 Breast Cancer Treatment Studies Cancer Research 4 works
- 10 Chronic Lymphocytic Leukemia Research Genetics 4 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Texas Oncology's research output changed?
Output in 2018–2022 was 5% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Oklahoma City
- University of Oklahoma Health Sciences Center
- Oklahoma State University Oklahoma City
- Oklahoma Medical Research Foundation
- Oklahoma City University
- Deaconess Hospital
- University of Oklahoma Medical Center
- Oklahoma State Department of Health
- Mercy Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.